Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Accounts Payables (2019 - 2026)

Immunovant filings provide 7 years of Accounts Payables readings, the most recent being $8.6 million for Q4 2025.

  • Quarterly Accounts Payables fell 56.52% to $8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.6 million through Dec 2025, down 56.52% year-over-year, with the annual reading at $17.7 million for FY2025, 146.76% up from the prior year.
  • Accounts Payables hit $8.6 million in Q4 2025 for Immunovant, up from $6.9 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $26.5 million in Q2 2023 and bottomed at $1.1 million in Q2 2022.
  • Average Accounts Payables over 5 years is $9.7 million, with a median of $7.5 million recorded in 2022.
  • Peak annual rise in Accounts Payables hit 2382.08% in 2023, while the deepest fall reached 92.74% in 2023.
  • Immunovant's Accounts Payables stood at $3.8 million in 2021, then soared by 265.93% to $14.0 million in 2022, then crashed by 72.08% to $3.9 million in 2023, then soared by 406.8% to $19.8 million in 2024, then tumbled by 56.52% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Accounts Payables are $8.6 million (Q4 2025), $6.9 million (Q3 2025), and $7.8 million (Q2 2025).